Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Menopause ; 31(9): 801-808, 2024 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-38954491

RESUMO

OBJECTIVE: To compare patient satisfaction rate in postmenopausal women who chose dynamic quadripolar radiofrequency or topical estrogens as their preferred treatment for genitourinary syndrome of menopause. METHODS: Patients were divided into two groups according to their preference: one was treated with estrogen therapy (ET) and the other with dynamic quadripolar radiofrequency treatment (RF). All patients included fulfilled a series of validated questionnaires, at baseline and at the 6-mo follow-up, in order to evaluate the discomfort degree associated with the presence of vulvovaginal atrophy and the impact of the reported symptoms on QoL and sexuality. RESULTS: After propensity score matching, the proportion of women considering themselves satisfied with their genital health conditions was extremely small at study entry (5.2% of the RF group and 6.9% of the ET group), while at a 6-mo follow-up, it increased to 46.7% and 46.6%, respectively. No statistically significant between-group differences were found regarding mean numerical rating scale scores for dryness and dyspareunia at follow-up (5.6 ± 2.6 vs 5.3 ± 2.3, P = 0.5; and 2.9 ± 2.5 vs 3.0 ± 2.7, P = 0.46). At 6-mo follow-up, we observed no statistically significant differences between the two groups regarding the other items evaluated. RF treatment was overall well tolerated. CONCLUSION: The use of quadripolar radiofrequency devices seems effective, but it is not associated with better clinical outcomes compared with topical hormone treatment, which is a substantially cheaper and more convenient treatment for genitourinary syndrome of menopause. Therefore, we suggest limiting the use of dynamic quadripolar radiofrequency selectively when topical estrogens are not effective, not tolerated, or contraindicated.


Assuntos
Atrofia , Estrogênios , Preferência do Paciente , Pós-Menopausa , Vagina , Vulva , Humanos , Feminino , Pessoa de Meia-Idade , Vulva/patologia , Vagina/patologia , Estrogênios/administração & dosagem , Estrogênios/uso terapêutico , Dispareunia/tratamento farmacológico , Dispareunia/terapia , Inquéritos e Questionários , Terapia de Reposição de Estrogênios/métodos , Satisfação do Paciente , Qualidade de Vida , Idoso , Terapia por Radiofrequência/métodos , Resultado do Tratamento , Doenças Vaginais/tratamento farmacológico , Doenças Vaginais/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA